Acasti Pharma Inc - Ordinary Shares - Class A
ACST
Get informed when a big investor buys or sells
+ FollowMarket Cap$34.17M
Close$
$1.74
48.4% downside
Current Fair Value
48.4% downsideOvervalued by 48.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $34.17 Million |
|---|---|
| Enterprise Value | $17.19 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.47 |
| Beta | 1.52 |
| Outstanding Shares | 16,510,632 |
Return
| Return on Equity | -14.86% |
|---|---|
| Return on Assets | -14.24% |
| Return on Invested Capital | -8.71% |
Valuation & Multiples
| P/E Ratio | -3.74 |
|---|---|
| PEG | -7.98 |
| Price to Sales | - |
| Price to Book Ratio | 1.12 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -3.06 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
November 13, 2025
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Acasti Pharma Inc
CEO: Janelle D'Alvise